NCT00030446 2020-04-08
Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Canadian Cancer Trials Group
Phase 2 Completed
Clinical Trials
8 trialsNCT00520013 2018-07-27
Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01003938 2016-06-30
Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer
NYU Langone Health
Phase 2 Terminated
NCT00059787 2015-12-01
Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00126542 2014-05-14
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00030485 2014-01-27
Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00031993 2013-01-17
Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix
National Cancer Institute (NCI)
Phase 2 Completed
NCT00130520 2012-05-28
Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer
University of Arizona
Phase 2 Completed